Tag Archives: NASDAQ:WCRX

Healthcare Sector Snapshot: Unilife, Affymax, Cell Therapeutics, Ariad, Warner

Posted on May 22, 2013 by Thomas Vedder

Unilife Corp’s (NASDAQ:UNIS) stock hiked 14.20% or +0.49 cent to settle at $3.94 on Tuesday.

Unilife Corp (NASDAQ:UNIS) last session’s volume of 4.45 million shares was higher than its average volume of 1.61 million shares. The stock after opening at …

Posted in Healthcare, Latest Headlines | Tagged AFFY, Affymax, ARIA, Ariad Pharmaceuticals, Cell Therapeutics, CTIC, NASDAQ:AFFY, NASDAQ:ARIA, NASDAQ:CTIC, NASDAQ:UNIS, NASDAQ:WCRX, Unilife, UNIS, Warner Chilcott, WCRX | Comments Off

Healthcare Giant News Buzz: Actavis (NYSE:ACT), Warner Chilcott (NASDAQ:WCRX) – ACT, WCRX, JNJ, THRX, HALO, PPHM, MYL

Posted on May 21, 2013 by Thomas Vedder

Investors responded negatively to the healthcare stocks on Monday. Key movement were observed in Theravance Inc (NASDAQ:THRX) and Halozyme Therapeutics, Inc (NASDAQ:HALO) on percentage decliners side while Peregrine Pharmaceuticals (NASDAQ:PPHM) was prominent stock on percentage gainer side.

The Parsippany, New …

Posted in Healthcare, Latest Headlines | Tagged ACT, Actavis, HALO, Halozyme Therapeutics, JNJ, Johnson, MYL, Mylan, NASDAQ:HALO, NASDAQ:MYL, NASDAQ:PPHM, NASDAQ:THRX, NASDAQ:WCRX, NYSE:ACT, NYSE:JNJ, Peregrine Pharmaceuticals, PPHM, Theravance, THRX, Warner Chilcott, WCRX | Comments Off

Actavis Inc. (NYSE:ACT) Plans to Buy Warner Chilcott (NASDAQ:WCRX) in Swap Deal

Posted on May 20, 2013 by Geoff Noir

business 6 Actavis Inc. (NYSE:ACT) would purchase Warner Chilcott (NASDAQ:WCRX) in a stock swap that prices the specialty pharmaceutical company at $8.5 billion, the firms declared Monday.

According to the terms of the agreement, Warner Chilcott stockholders would get 0.16 shares of …

Posted in Latest Headlines | Tagged ACT, Actavis, NASDAQ:WCRX, NYSE:ACT, Warner Chilcott, WCRX | Comments Off

U.S. Stock Market Movers: Warner Chilcott (NASDAQ:WCRX), Charter Communications (NASDAQ:CHTR) – CHTR, WCRX

Posted on February 25, 2013 by Geoff Noir

Warner Chilcott Plc (NASDAQ:WCRX) announced on Friday that its net income moved up in the Q4 as its expenses tumbled.

Irish drug manufacturer’s net income surged to $124 million or 49 cents a share, from $90 million or 36 cents …

Posted in Latest Headlines | Tagged Charter Communications, CHTR, NASDAQ:CHTR, NASDAQ:WCRX, Warner Chilcott, WCRX | Comments Off

Warner Chilcott (NASDAQ:WCRX) Beats Fiscal Fourth Quarter Results – WCRX, ACT, NVS, GSK

Posted on February 25, 2013 by Thomas Vedder

The Dublin, Ireland-based Warner Chilcott Plc (NASDAQ:WCRX) announced fiscal Q4 profit hiked from previous year, showing lower costs and sales expenses in many key promoted products, mainly LO Loestrin FE and Asacol. Both adjusted cash EPS and quarterly revenues surpassed …

Posted in Healthcare, Latest Headlines | Tagged ACT, Actavis, GlaxoSmithKline, GSK, NASDAQ:WCRX, Novartis AG, NVS, NYSE:ACT, NYSE:GSK, NYSE:NVS, Warner Chilcott, WCRX | Comments Off

Warner Chilcott (NASDAQ:WCRX) Getting Ready to Post Quarterly Results; Held Conference Call on Feb. 22 – WCRX, ACT, NVS, SHPG

Posted on February 19, 2013 by Thomas Vedder

Specialty pharmaceutical company Warner Chilcott Plc (NASDAQ:WCRX) reported that it will provide its fiscal Q4 and full year 2012 financial results earlier to the market opening on Friday, February 22, 2013.

The corporation will host a conference call for all …

Posted in Healthcare, Latest Headlines | Tagged ACT, Actavis, NASDAQ:SHPG, NASDAQ:WCRX, Novartis AG, NVS, NYSE:ACT, NYSE:NVS, Shire PLC, SHPG, Warner Chilcott, WCRX | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.